Should a Pharma Company Relocate from Canada to the US?
This paper examines whether a pharmaceutical company operating near Toronto, Canada, should relocate its operations to Colorado, United States. Drawing on financial considerations such as land value, lower U.S. tax burdens, reduced labor costs, and trade efficiencies enabled by NAFTA, the analysis also addresses non-financial factors including public perception, corporate social responsibility, workforce replacement, regulatory differences, and political blowback. Using the Burger King corporate inversion controversy and the Turing Pharmaceuticals scandal as illustrative cases, the paper recommends a structured twelve-month review process before any final decision is made, concluding that the move should only proceed if its total benefits clearly outweigh the reputational and operational costs involved.
- Introduction: Overview of relocation question and key factors
- Financial Case for Relocation: Land value, taxes, labor costs, and NAFTA benefits
- Non-Financial and Reputational Considerations: Public perception, political blowback, and industry scrutiny
- Proposed Twelve-Month Decision Framework: Structured review timeline before committing to move
- Conclusion: Final recommendation balancing profit and responsibility
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper balances quantitative financial considerations (land value, tax differentials, labor costs) with qualitative concerns (public perception, corporate social responsibility, regulatory risk), giving the analysis real-world depth.
- It draws on concrete, well-known cases — the Burger King corporate inversion and the Turing Pharmaceuticals controversy — to ground abstract business considerations in recognizable events.
- The proposed twelve-month decision framework transforms the analysis from purely evaluative into action-oriented, demonstrating applied business thinking.
Key academic technique demonstrated
The paper effectively uses comparative case analysis to contextualize a hypothetical business decision. By referencing real corporate decisions (Burger King's inversion consideration, Turing Pharma's regulatory troubles), the author connects theoretical business principles — including Milton Friedman's shareholder primacy model — to lived outcomes, strengthening the credibility of the recommendations.
Structure breakdown
The paper opens with a brief framing introduction, moves into a detailed analysis section covering both financial and non-financial factors, embeds a proposed action timeline within the analysis, and closes with a concise conclusion. The single "Analysis" section handles most of the argumentative weight, and the conclusion synthesizes the key tension between shareholder interests and broader stakeholder concerns without overstating certainty in either direction.
Introduction
This paper considers whether a pharmaceutical company operating just outside Toronto should relocate to the United States — specifically to Colorado — in light of several compelling factors. Those factors include the high market value of the company's Canadian land, the comparatively greater tax and labor costs of doing business in Canada, the trade efficiencies created by the North American Free Trade Agreement (NAFTA), and related financial incentives. While the case for moving may appear straightforward on its surface, the decision is far more nuanced. Both financial and non-financial considerations deserve careful attention before any commitment is made.
References
Ferdman, R. (2014). We finally have an idea of how much money Burger King will save by moving to Canada. Washington Post. Retrieved 24 February 2016, from https://www.washingtonpost.com/news/wonk/wp/2014/12/11/burger-king-could-save-a-whopping-amount-of-money-by-moving-to-canada/
Friedman, M. (1970). The social responsibility of business is to increase its profits. Colorado.edu. Retrieved 24 February 2016, from
Mullin, E. (2016). Turing Pharma says Daraprim availability will be unaffected by Shkreli arrest. Forbes.com. Retrieved 24 February 2016, from http://www.forbes.com/sites/emilymullin/2015/12/21/turing-pharma-says-daraprim-availability-will-be-unaffected-by-shkreli-arrest/#11db056c2e82
Create your account
Always verify citation format against your institution’s current style guide requirements.